Holen Sie sich die Stockscreener-App
1.99
3.11%
0.06
Schlusskurs vom Vortag:
$1.93
Offen:
$1.97
24-Stunden-Volumen:
5.14M
Relative Volume:
0.66
Marktkapitalisierung:
$652.52M
Einnahmen:
$4.41M
Nettoeinkommen (Verlust:
$-67.85M
KGV:
-8.8131
EPS:
-0.2258
Netto-Cashflow:
$-57.15M
1W Leistung:
+13.07%
1M Leistung:
-18.78%
6M Leistung:
+24.37%
1J Leistung:
+192.91%
1-Tages-Spanne:
$1.96
$2.035
1-Wochen-Bereich:
$1.71
$2.035
52-Wochen-Spanne:
$0.64
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.99 | 652.52M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) completes OCU400 Phase 3 enrollment; financing extends runway - Stock Titan
Ocugen's Triple-Threat Gene Therapy Pipeline Faces a Cash Countdown - AD HOC NEWS
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Ocugen, Inc. outlines mass-market gene therapy push with planned BLAs for blindness treatments - Traders Union
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update - MarketBeat
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial - Traders Union
[SCHEDULE 13G] Ocugen, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Forecast, Price Target & Analyst Ratings | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen's Financial Lifeline Fuels High-Stakes Gene Therapy Push - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Stock Receives 'Moderate Buy' Rating from Analysts - National Today
Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
OCU410 shows nearly double treatment effect over approved therapies, Ocugen, Inc. asserts - Traders Union
Ocugen's Gene Therapy Ambitions Fueled by Clinical and Financial Milestones - AD HOC NEWS
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Benzinga
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
Ocugen Secures Financial Runway as Gene Therapy Pipeline Accelerates - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.43% to 11.37 - MSN
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial - MyChesCo
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Pharma News: Will Ocugen Inc stock recover after earningsTreasury Yields & Community Consensus Picks - baoquankhu1.vn
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Aug Macro: Is Ocugen Inc undervalued by DCF analysisWeekly Stock Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - Yahoo Finance
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - investing.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - bitget.com
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - za.investing.com
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
$Ocugen (OCGN.US)$ - Moomoo
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.19%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):